Brief: BCAL Diagnostics Enters Into Exclusive Licence Agreement With Clearnote Health
18/09/2025 02:28
Sept 18 (Reuters) - BCAL Diagnostics Ltd BDX.AX: ENTERED INTO EXCLUSIVE LICENCE AGREEMENT WITH CLEARNOTE HEALTH DEAL FOR DISTRIBUTION OF CLEARNOTE'S PANCREATIC, OVARIAN CANCER BLOOD TESTS IN AUSTRALIA, NZ Further company coverage: BDX.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on BCAL Diagnostics
See all newsAustralia's Genetic Signatures urges largest stakeholder to clarify merger intentions; shares rise
Brief: BCAL Diagnostics Introduces Avantect Multi-Cancer Early Detection Test
Brief: BCAL Diagnostics Clarifies Of Bcal's Position In Relation To Genetic Signatures
Brief: Genetic Signatures Requested BCAL Diagnostics To Clarify Details Of Shareholdings, Associates In Co
Brief: BCAL To Acquire Shares In Genetic Signatures